disulfiram has been researched along with bortezomib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cao, H; Chen, H; Han, X; Huang, Y; Liu, J; Peng, C; Rao, L; Ren, Y; Sheng, C; Su, C; Tu, J; Wan, C; Wan, J; Wen, W | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gullbo, J; Larsson, R; Lövborg, H; Nygren, P; Oberg, F; Rickardson, L | 1 |
| Cvek, B; Dvorak, Z | 1 |
| Goel, A; McCormick, ML; Salem, K; Wendlandt, E; Zhan, F | 1 |
| Chen, W; Fan, B; Li, T; Xiao, Z; Yang, J; Zhao, Y | 1 |
| Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M | 1 |
| Hasinoff, BB; Patel, D | 1 |
| Arima, Y; Hata, H; Kawano, Y; Kushima, S; Matsuoka, M; Sasano, T; Tsujita, K | 1 |
| Bacovsky, J; Bartek, J; Buchtova, T; Chroma, K; Gursky, J; Mistrik, M; Moudry, P; Skrott, Z | 1 |
2 review(s) available for disulfiram and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Topics: Alcohol Deterrents; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disulfiram; Drug Screening Assays, Antitumor; Forecasting; Humans; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thiocarbamates; Ubiquitin | 2008 |
11 other study(ies) available for disulfiram and bortezomib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of
Topics: Allosteric Site; Antifungal Agents; Azoles; Biofilms; Candida albicans; Candida parapsilosis; Drug Resistance, Fungal; Enzyme Inhibitors; Fructose-Bisphosphate Aldolase; Fungal Proteins; Microbial Sensitivity Tests; Molecular Structure; Protein Binding; Structure-Activity Relationship | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Inhibition of proteasome activity, nuclear factor-KappaB translocation and cell survival by the antialcoholism drug disulfiram.
Topics: Alcohol Deterrents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cycloheximide; Disulfiram; Dose-Response Relationship, Drug; Humans; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Pyrazines; Pyrrolidines; Thiocarbamates; Tumor Necrosis Factor-alpha | 2006 |
Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
Topics: Adult; Apoptosis; Bortezomib; Cell Line, Tumor; Disease-Free Survival; Disulfiram; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Male; Middle Aged; Multiple Myeloma; Oxidative Stress; Reactive Oxygen Species; Superoxide Dismutase | 2015 |
Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Topics: AC133 Antigen; Acetaldehyde Dehydrogenase Inhibitors; Adenoma; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Bortezomib; Cell Survival; Dacarbazine; Disulfiram; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nestin; Peptides; Pituitary Neoplasms; Primary Cell Culture; Proteasome Inhibitors; Proteolysis; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitination; Xenograft Model Antitumor Assays | 2015 |
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea | 2016 |
Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Antineoplastic Agents; Bortezomib; Cell-Free System; Disulfiram; Humans; Kinetics; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Binding | 2017 |
A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Datasets as Topic; Disulfiram; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Ketone Oxidoreductases; Mitochondria; Molecular Targeted Therapy; Morpholines; Multiple Myeloma; Phosphorylation; Plasma Cells; Pyruvate Dehydrogenase Acetyl-Transferring Kinase | 2022 |
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Disulfiram; Drug Repositioning; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Endopeptidase Complex; Proteasome Inhibitors | 2022 |